GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia by Venditti, A. et al.
Regular Article
CLINICAL TRIALS AND OBSERVATIONS
GIMEMA AML1310 trial of risk-adapted, MRD-directed
therapy for young adults with newly diagnosed acute
myeloid leukemia
Adriano Venditti,1,2 Alfonso Piciocchi,3 Anna Candoni,4 Lorella Melillo,5 Valeria Calafiore,6 Roberto Cairoli,7 Paolo de Fabritiis,8 Gabriella Storti,9
Prassede Salutari,10 Francesco Lanza,11 Giovanni Martinelli,12,13 Mario Luppi,14 Patrizio Mazza,15 Maria Paola Martelli,16 Antonio Cuneo,17
Francesco Albano,18 Francesco Fabbiano,19 Agostino Tafuri,20 Anna Chierichini,21 Alessia Tieghi,22 Nicola Stefano Fracchiolla,23
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Ematologia Università degli Studi Sapienza, Rome, Italy; and 26A. O. Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
KEY PO INT S
l A risk-adapted, MRD-
driven transplant










We designed a trial in which postremission therapy of young patients with de novo acute
myeloid leukemia (AML) was decided combining cytogenetics/genetics and postconsolidation
levels of minimal residual disease (MRD). After induction and consolidation, favorable-risk
patients (FR) were to receive autologous stem cell transplant (AuSCT) and poor-risk
patients (PR) allogeneic stem cell transplant (AlloSCT). Intermediate-risk patients (IR)
were to receive AuSCT or AlloSCT depending on the postconsolidation levels of MRD.
Three hundred sixty-one of 500 patients (72%) achieved a complete remission, 342/361
completed the consolidation phase and were treatment allocated: 165 (48%) to AlloSCT
(122 PR, 43 IR MRD-positive) plus 23 rescued after salvage therapy, for a total of 188
candidates; 150 (44%) to AuSCT (115 FR, 35 IR MRD-negative) plus 27 IR patients (8%)
with no leukemia-associated phenotype, for a total of 177 candidates. Overall, 110/177
(62%) and 130/188 (71%) AuSCT or AlloSCT candidates received it, respectively. Two-
year overall (OS) and disease-free survival (DFS) of the whole series was 56% and 54%,
respectively. Two-year OS and DFSwere 74% and 61% in the FR category, 42% and 45% in the PR category, 79% and
61% in the IR MRD-negative category, and 70% and 67% in the IR MRD-positive category. In conclusion, AuSCT may
still have a role in FR and IRMRD-negative categories. In the IRMRD-positive category, AlloSCT prolongs OS and DFS
to equal those of the FR category. Using all the available sources of stem cells, AlloSCT was delivered to 71% of the
candidates.This trial was registered at www.clinicaltrials.gov as #NCT01452646 and EudraCT as #2010-023809-36.
(Blood. 2019;134(12):935-945)
Introduction
Despite the continuously growing knowledge about the genetic
and molecular landscape of acute myeloid leukemia (AML),1-6
the paradigm of treatment of young adults with AML is still largely
based on the “one-size-fits-all” approach, with postremission
strategies still depending on donor availability rather than on the
actual risk of disease relapse.7 In the short term, this has led to
satisfactory rates of complete remission (CR) (70%-80%), but in
the long-term survival, estimates are still disappointing, with,30%
to 40% of patients becoming long-term survivors.8,9
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Indeed, dealing with the high propensity for relapse and the
considerable genetic heterogeneity of AML requires either
development of new agents or adoption of modern, risk-adapted
therapeutic programs. Risk-adapted approaches may consist of
integrating pretreatment prognosticators, such as cytogenetics
and molecular genetics, with posttreatment parameters, such as
assessment of minimal (or measurable) residual disease (MRD).10
Even though in AML cytogenetic is a historical and robust de-
terminant of outcome, the modern stratification of the patients
in “favorable-risk" (FR), “intermediate-risk” (IR), or “adverse-risk”
categories relies ever more increasingly on the baseline mo-
lecular pattern.11,12 Based on this, FR patients achieve overall
survival (OS) and disease-free survival (DFS) rates of 50% to 60%
at 3 to 5 years with standard chemotherapy, whereas those
with adverse risk show OS and DFS rates of 5% to 20% at 3 to
5 years if not submitted to allogeneic stem cell transplantation
(AlloSCT).7,11,13 Therefore, it appears that in FR and adverse-risk
patients, the sole genetic/cytogenetic profile, regardless of the
MRD levels, is helpful enough to guide decisions for the delivery
of AlloSCT in the postremission phase. On the other hand, there
are no accepted criteria to direct the decision-making process
after consolidation for patients in the IR category: for these
patients, evaluation of the MRD status appears appropriate to
extrapolate those at high (MRD positive) or low (MRD negative)
risk of relapse, for whom differentiated treatments may be
adopted.
Although MRD assessment in AML is prognostic,14-18 still ,50%
of relapses are detected by MRD; thus, the false negative rate is
still high, resulting in low specificity. Moreover, MRD is assessed
exploiting disparate flow cytometry or molecular protocols so
that its use for treatment decisions in AML is still at an early stage.
Depending on the technical platforms and targets, a sensitivity
of 1023 to 1026 is reported.19 In particular, we observed that
the integrated evaluation of baseline prognosticators and MRD
improves risk assessment and helps optimizing postremission
therapy.20 In fact, directing MRD-positive patients toward in-
tensified therapy like AlloSCT while sparing thoseMRD-negative
patients the procedure-related morbidity and mortality may be
highly beneficial in terms of toxicity minimization.10
Considering all the above, the Gruppo Italiano Malattie
EMatologiche dell’Adulto (GIMEMA) Foundation has developed
a risk-adapted, MRD-oriented, prospective clinical trial, the
strategy of which consisted of the prognostic integration of
pretreatment cytogenetics and genetics with postconsolidation
MRD, as detected by multiparametric flow cytometry (MFC).
Based on this strategy, patients were to receive postconsolidation
autologous stem cell transplantation (AuSCT) or AlloSCT, re-
spectively, depending on their risk profile. We report here the
final analysis of this multicenter study.
Patients and methods
Patients
Previously untreated patients with a diagnosis of de novo
AML according to the World Health Organization diagnostic
criteria21 were recruited to the GIMEMA AML1310 Study (EudraCT
#2010-023809-36; www.clinicaltrials.gov Identifier #NCT01452646)
provided they met the criteria for eligibility (see supplemental
Material, available on the Blood Web site). The study was ap-
proved by the ethics committees of the participating hospitals/
academic institutions and was conducted in accordance with
the Declaration of Helsinki. All participants gave their informed
consent.
Study design
The main objective of the study was to verify whether the de-
livery of a postremission therapy, the intensity of which was risk
driven, improved the outcome of adult patients with AML in
terms of increased antileukemic efficacy. The primary endpoint
of the study was OS at 24 months from treatment start; for
comparative purposes, we included a historical control con-
sisting of patients recruited to the previous LAM99P GIMEMA
trial.1 Secondary endpoints were CR or complete remission in-
complete (CRi) rate after induction, DFS, and cumulative in-
cidence of relapse (CIR) from CR. Upfront evaluation included
bone marrow (BM) aspirate for morphology, cytogenetics,
molecular genetics, and MFC analysis. The baseline MFC as-
sessment was a necessary step, not only for diagnostic purposes
but also to identify leukemia-associated immunophenotypes
(LAIPs). Identification of baseline LAIPs was the essential re-
quirement for monitoring MRD after therapy; at the established
time point, BM MRD was determined by a high-sensitivity
8-color MFC assay. Based on several retrospective validations
in the context of former European Organization for the Research
and Treatment of Cancer/GIMEMA protocols,22 the threshold
for discriminating MRD-negative from MRD-positive cases was
set at 3.5 3 1024 residual leukemic cells, and the selected time
point was the postconsolidation phase, once the hematologic
recovery was complete. Patients were studied at diagnosis for
the presence of RUNX1-RUNX1T1 or CBFb/MYH11 rearrange-
ments, defining core binding factor (CBF) leukemias, and for
NPM1, FLT3, and c-KIT mutations. In CBF or NPM1-positive
AML, MRD was investigated as reported elsewhere.14,23,24 Mo-
lecular analysis, LAIPs assessment, and postconsolidation MRD
determinations were centralized at Laboratorio di Diagnostica
Integrata Oncoematologica “OPPO”, at Tor Vergata University
Hospital of Rome, whereas conventional karyotype was carried
out at local institutions. Response to treatment was assessed on
BM and peripheral blood, according to the recommendations of
an international working group.25 Patients who did not achieve
CR/CRi or PR after the first induction course or CR/CRi after
2 induction courses were considered treatment failures. The
AML1310 trial was designed at a time when European Leuke-
miaNet 2010/2017 and National Comprehensive Cancer Net-
work (NCCN) 2018 recommendations were not yet published.
Therefore, when the trial regulatory path was concluded, we
started recruiting and stratifying patients according to con-
temporary classification, that was the NCCN 2009, version 1.26
For the purpose of our study, 4 categories of risk were identified
(Table 1): favorable-risk (NCCN-FR) or poor-risk (NCCN-PR)
patients, who were submitted to AuSCT or AlloSCT, respectively;
intermediate-MRD negative (NCCN-IR-Neg) or positive (NCCN-
IR-Pos) patients, who were to receive AuSCT or AlloSCT,
respectively. Moreover, we enucleated a fifth group of patients
belonging to the IR category, in whom we failed to identify any
LAIP (NCCN-IR-no-LAIP category); these patients were allocated
to the AuSCT postconsolidation option. AlloSCT andAuSCTwere
to be performed within 3 months of the end of the consolidation
course.
















Induction consisted of IV daunorubicin 50mg/m2 daily on days 1,
3, and 5; IV etoposide 50 mg/m2 daily on days 1 to 5; and IV
cytarabine 100 mg/m2 as a daily continuous infusion, days 1 to
10. All patients in CR/CRi, after 1 to 2 induction cycles, received
1 consolidation course consisting of IV daunorubicin 50 mg/m2
daily on days 4,×5, and 6 and IV cytarabine 500 mg/m2 every
12 hours on days 1 to 6. In patients belonging to NCCN-FR and
NCCN-IR categories, peripheral blood stem cell collection was
attempted by initiating, on day 20 from the start of consolidation
therapy, granulocyte colony-stimulating factor until completion
of stem cell collection. In the case of failure to collect a sufficient
number of peripheral blood stem cells, BMwas used as a source.
In the case of poor BM harvest, instead of AuSCT, patients
were to receive a second consolidation course with high-dose
cytarabine (HDARAC). Postconsolidation therapy was based
on risk allocation: NCCN-FR patients were to receive AuSCT;
NCCN-PR patients were to receive AlloSCT; NCCN-IR patients
were to receive AuSCT or AlloSCT depending on the levels
of BM MRD as measured by MFC, after consolidation therapy.
Allocation to AlloSCT required the procedure to be performed
whatever the source of stem cells (HLA-identical sibling, HLA-
identical unrelated donor, cord blood, HLA-haploidentical sibling).
Salvage therapy consisted of 1 or 2 courses of IV fludarabine
30 mg/m2 daily, on days 1 to 5; cytarabine 2000 mg/m2 daily,
on days 1 to 5; idarubicin 8 mg/m2 daily, on days 1 to 3. Whatever
the original NCCN risk category of assignment, patients with
resistant disease after 1 to 2 cycles of induction therapy were
considered PR and allocated to the AlloSCT procedure once
CR/CRi was achieved.
Statistical analysis and sample size calculation
The primary objective was the percentage of OS at 2 years.
An estimated number of 213 subjects were initially required
to accomplish this primary objective. This sample size was to
achieve a 90% power to detect a difference of 10% between the
null hypothesis that OS at 2 years is 50% and the alternative
hypothesis that OS is 60%, using a single-stage phase 2 design
with a 5% significance level (based on data of the historic con-
trol group GIMEMA LAM99P).1 Based on the historical control
group, we also considered that ;70% of the observed patients
would have been classified as IR, therefore allowing attainment
of the figure of 150 patients available for MRD-driven treatment
allocation. However, after 173 subjects were enrolled, only
56 belonged to the IR category (32% vs 70% expected). Therefore,
to reach the target of 150 subjects belonging to the IR category,








Median WBCc (range) 14 3 109/L (0.16-352)
Cytogenetics: FR, n (%) 47 (11)
Cytogenetics: IR, n (%) 315 (73)
Cytogenetics: PR, n (%) 67 (16)
RUNX1/RUNX1T1, n (%) 27 (5)
RUNX1/RUNX1T1/c-KITmut, n (%) 12/27 (44)
CBFb/MYH11, n (%) 37 (7)
CBFb/MYH11/c-KITmut, n (%) 4/37 (11)
FLT3-ITDmut, n (%) 46 (9)
NPM1mut, n (%) 107 (21)
NPM1mut/FLT3-ITDmut, n (%) 80 (16)
NCCN-FR, n (%) 138 (28)
NCCN-IR, n (%) 127 (25)
NCCN-IR-no LAIP, n (%) 47 (9)
NCCN-PR, n (%) 188 (38)
WBCc, white blood cell count.






RUNX1/RUNX1T1 without c-Kit mutations
CBFb/MYH11 without c-Kit mutations
NPM1 mutation without FLT3 mutations




Other karyotypic abnormalities not listed as FR or PR
RUNX1/RUNX1T1 with c-Kit mutation
CBFb/MYH11 with c-Kit mutation
No NPM1 mutations
No FLT3-ITD mutations
3. NCCN-IR postconsolidation MRD positive
As in 2 but with measurable MRD after the consolidation course
4. NCCN-PR
Complex karyotype ($3 abnormalities)
25/5q-
27/7q-






Patients belonging to the IR category in whom no leukemia
associated
Immunophenotype (LAIP) was identified, at diagnosis
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an amendment to the protocol was adopted in 2013, and the
sample size was adjusted to 515 subjects to recruit. The efficacy
analysis was performed as per treatment received, including
individuals who commenced induction therapy and censoring
patients at the time when they received a nonassigned treat-
ment. OS (time elapsed from treatment start to death) and DFS
(time from CR to relapse or death in remission) were calculated
using the Kaplan-Meier product limit estimator. Differences in
terms of OS and DFS were evaluated by means of Log-Rank test
in univariate analysis and by means of Cox regression model
in multivariate analysis, after assessment of proportionality of
hazards. All variables with a P value , .15 in univariate analysis
were considered in the multivariate models. The influence of the
transplant (AuSCT and AlloSCT) on the survival outcome was
evaluated in the Cox model by means of a time-dependent
covariate. CIR was estimated by cumulative incidence curves
using the proper nonparametric method. Patients’ and disease
characteristics were summarized by means of cross-tabulations
for categorical variables or by quintiles for continuous variables.
Differences between categorical variables or response rates in
subgroups were tested by the x2 or Fisher exact tests, as ap-
propriate. Confidence intervals (CIs) were calculated at 95%
level, and all tests were 2 sided, accepting P # .05 as indicating
a statistically significant difference. All analyses were performed
using the SAS (version 9.4) and R (R Foundation for Statistical
Computing, Vienna, Austria) system software. Study data were
collected and managed using the REDCap20 electronic data
capture tools hosted at GIMEMA Foundation.
Results
Between January 2012 andMay 2015, 515 patients with de novo
AML, seen at 55 GIMEMA institutions, were registered to the
trial. Fifteen patients did not commence induction because of
pretherapy death, infections, or ineligibility, and 500 started
treatment and were available for the analysis. Demographic
characteristics are summarized in Tables 2 and 3. Median age
was 49 (18-60.9) years, and 52% were men. For 429 evaluable
patients, cytogenetic distribution was favorable, intermediate,
and poor in 11%, 73%, and 16%, respectively. Among 500 cases,
RUNX1/RUNX1T1 was detected in 27 (5%) with 12 (44%) also
c-KITmutated; CBFb/MYH11was positive in 37 (7%) with 4 (11%)
also c-KIT mutated, and FLT3-ITD and NPM1 mutations were
detected in 46 (9%) and in 107 (21%), respectively. Finally,
concomitant mutations of NPM1 and FLT3-ITD were observed in
80 cases (16%).We found no instances of FLT3mutations in CBF-
positive AML. Based on these data, patients’ distribution within
the risk categories was as follows: 138 (28%) were NCCN-FR,
127 (25%) were NCCN-IR, 47 (9%) were NCCN-IR-no-LAIP, and
188 (38%) were NCCN-PR. Patients’ disposition is illustrated in
Figure 1. After the first induction cycle, 333 (67%) and 21 (4%)
patients achieved a CR and CRi, respectively. A second in-
duction course was delivered to 10 of 13 patients in PR, with 7
entering CR. Therefore, after 1 to 2 cycles of induction, 361 (72%)
patients obtained a CR: 88% in the NCCN-FR category, 65% and
69% in the NCCN-IR and NCCN-PR category, respectively
(P , .001). Eighty-four (17%) patients had a refractory AML and
63 of them received a salvage therapy; 23 of these 63 (37%)
achieved a CR. Three hundred forty-two of 361 (95%) patients
started the consolidation phase and were treatment allocated:
177 (52%) to AuSCT (115 [65%] NCCN-FR, 35 [20%] NCCN-IR-
Neg, 27 [15%] NCCN-IR-no-LAIP) and 165 (48%) to AlloSCT
(122 [74%] NCCN-PR, 43 [26%] NCCN-IR-Pos). Of the 177
AuSCT candidates, 110 (62%) were transplanted (78 [71%]
NCCN-FR, 20 [18%] NCCN-IR-Neg, 12 [11%] NCCN-IR-no-LAIP).
Of the 165 AlloSCT candidates, 110 (67%) were transplanted
(78 [71%] NCCN-PR, 32 [29%] NCCN-IR-Pos). If we include also
the 23 patients who achieved a CR after salvage therapy, the
group of AlloSCT candidates enlarges to 188. Because 20 of these
23 patients were given AlloSCT, the number of AlloSCT candidates
who received it was 130/188 (71%). For the 78patients belonging to
theNCCN-PR category, the source of stemcells was aHLA-identical
sibling in 26, a HLA-identical unrelated donor in 34, umbilical cord
blood in 1, andHLA-haploidentical sibling in 17; for the 32 belonging
to the NCCN-IR-Pos category, the source of stem cells was a HLA-
identical sibling in 12, a HLA-identical unrelated donor in 9, umbilical
cord blood in 1, and HLA-haploidentical sibling in 10. By physicians’
decision, 1 patient belonging to the NCCN-PR category received
AuSCT and 1 belonging to NCCN-FR category received AlloSCT.
OS, DFS, and CIR
OS and DFS rates at 24 months of our historical control were
49% (95%CI 47-52) and 55% (95%CI 52-59), respectively.1 In the
Table 3. Patients demographics and clinico-biologic characteristics according to treatment received
AlloSCT AuSCT HDARAC P
n 131 111 19
Median age (range) 46.7 (18-60.9) 48.4 (18-60.8) 54.7 (27-59.5) .033
Sex, n (%)
Male 66 (50) 59 (53) 10 (53) .909
Female 65 (50) 52 (47) 9 (47)
Median WBC (range) 12.9 3 109/L (0.16-352) 16.7 3 109/L (0.90-186) 11.6 3 109/L (1.24-102) .462
Risk category, n (%)
NCCN-FR 1 (1) 78 (71) 18 (95) ,.001
NCCN-IR 41 (32) 20 (18) 1 (5)
NCCN-PR 87 (66) 1 (1) 0 (0)
NCCN-IR-no LAIP 2 (1) 12 (10) 0 (0)
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present trial, after a median follow-up of 28.8 months, 2-year
OS was 56% (95%CI 52-61) with a median duration of 38months
(Figure 2), and DFS was 54% (95% CI 49-60) with a median
duration of 32.4 months (Figure 2). The estimated OS at
24 months of 56% was less than the alternative hypothesis of
60%. However, the upper value of 95% CI included also the
alternative hypothesis of 60% 2-year survival. Therefore, we
considered the trial as not conclusive with regards to the pri-
mary endpoint. CIR, considering death in CR as a competing
risk, was 33% (95% CI 28-38) (Figure 2). When splitting the
survival analysis according to the identified categories of risk,
2-year OS was 42% (95% CI 36-50) for NCCN-PR patients,
58% (95% CI 50-68) for NCCN-IR patients, 74% (95% CI 67-82)
for NCCN-FR patients, and 50% (95%CI 37-67) for NCCN-IR-no
LAIP patients (P , .0001) (Figure 3). Two-year DFS was
45% (95% CI 37-55) for NCCN-PR patients, 61% (95% CI 52-73) for
NCCN-IR patients, 61% (95% CI 52-71) for NCCN-FR patients, and
48% (95% CI 33-70) for those belonging to the NCCN-IR-no LAIP
category (P 5 0×026) (Figure 3). Using this risk-adapted ap-
proach, DFS duration of NCCN-FR and NCCN-IR was super-
imposable, whereas the NCCN-IR-no LAIP one was the shortest.
When we focused on the NCCN-IR patients, whose post-
consolidation choice was MRD-driven, no significant differ-
ences were observed in terms of 2-year OS between thoseMRD
negative (79% [95% CI 66-94]) and MRD positive (70% [95% CI
57-86]) (P5 .713) (Figure 4). The same was observed regarding
the 2-year DFS (MRD negative 5 61% [95% CI 47-80]; MRD
positive 5 67% [95% CI 53-83]) (P 5 .773) (Figure 4). The mul-
tivariate analysis confirmed the independent role of risk category
in affecting CR rate, duration of OS, and DFS. The transplant
procedure (AuSCT plus AlloSCT), analyzed as a time-dependent
variable, affected independently the duration ofOS. Age affected
independently the duration of OS and DFS, whereas WBCc
achievement of CR (supplemental Table 2).
NCCN-FR
• Lost to follow-up during the two
   years of follow-up (n=9)
NCCN-IR
• Lost to follow-up during the two
   years of follow-up (n=12)
NCCN-PR
• Lost to follow-up during the two
   years of follow- (n=12)
NCCN-IR-no-LAIP
• Lost to follow-up during the two
   years of follow-up (n=2)












• Lost fo Follow-up (n=2)
• Other reasons (n=3)
NCCN-FR
Allocated to intervention (n=138)
• Consolidation received: 115
• Second induction course: 2
• Salvage received: 2
• Did not Received post induction






• Received AUTO-graft after
   consolidation (n=78)
• Received High dose of
   cytarabine (n=18)
• Received ALLO-graft after
   salvage (n=1)
NCCN-IR
Allocated to intervention (n=127)
• Consolidation received: 78 (35
   NCCN-IR-Neg, 43 NCCN-IR-Pos)
• Second induction course: 2
• Salvage received: 23
• Did not Received post induction




Lost to follow up (n=1)
Other (n=4)
• Received AUTO-graft after
   consolidation (n=20)
• Received High dose of
   cytarabine (n=1)
• Received ALLO-graft after
   consolidation (n=32)
• Received ALLO-graft after
   salvage (=9)
NCCN-PR
Allocated to intervention (n=188)
• Consolidation received: 122
• Second induction course: 5
• Salvage received: 32
• Did not Received post induction






• Received ALLO-graft after
   consolidation (n=78)
• Received AUTO-graft after
   consolidation (n=1)
• Received ALLO-graft after
   salvage (n=9)
NCCN-IR-no-LAIP
Allocated to intervention (n=47)
• Consolidation received: 27
• Second induction course: 1
• Salvage received: 6
• Did not Received post induction





• Received AUTO-graft after
   consolidation (n=12)
• Received ALLO-graft after
   consolidation (n=1)
• Received ALLO-graft after
   salvage (n=1)
Figure 1. Consort diagram of patients’ disposition.
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MFC and molecular integrated evaluation of MRD
As an ancillary activity of the protocol, of 251 patients whose AML
was characterized by the presence of a molecular marker useful
for MRD assessment, we received 112 BM samples (RUNX-
RUNX1 5 9, CBFB-MYH11 5 9, and NPM1 5 94) at the post-
consolidation time point. In 60 of these, we had the opportunity
to combine the postconsolidation results of MFC and reverse
transcription quantitative polymerase chain reaction (RT-qPCR)
MRD studies. This integrated analysis identified 4 categories of
patients: double negative (MFCneg/PCRneg), double positive
(MFCpos/PCRpos), and single positive (MFCpos/PCRneg or
MFCneg/PCRpos). Patients who were double negative had
a 2-year OS and DFS of 89% (95% CI 71-100) and 69% (95% CI
44-100), respectively. Patients who were MFCpos/PCRneg had
a 2-year OS and DFS of 88% (95% CI 73-100) and 76% (95% CI
58-100), respectively. Patients who were MFCneg/PCRpos had
a 2-year OS and DFS of 87% (95% CI 72-100) and 65% (95% CI
45-92), respectively. Finally, patients who were double positive
had a 2-year OS and DFS of 55% (95% CI 34-87) and
22% (95% CI 9-58), respectively (Figure 5A-B; P 5 .037 and
.003, respectively).
AuSCT vs HDARAC consolidation
As per protocol, 19 patients (18 NCCN-FR and 1 NCCN-IR)
received HDARAC, because they did not have enough stem cells
collected. Figure 6 shows OS and DFS of these patients com-
pared with those who were submitted to AuSCT. OS was
83% (95%CI 67-100) and85% (95%CI 78-93), respectively (P5 .753);
DFSwas 68% (95%CI 50-93) and 63% (95%CI 54-73), respectively
(P 5 .595). Of these 19 patients, 15 were NCCN-FR MFCneg/
PCRneg, MFCpos/PCRneg, or MFCneg/PCRpos, 3 were NCCN-
FR MFCpos/PCRpos, and 1 was NCCN-IR MRD negative.
Discussion
The role of molecular and cytogenetic abnormalities in pre-
dicting response to therapy and survival in patients with AML has



























































500(0)N at risk (events) 326(148) 220(62) 61(11) 8(3)
12 24
Months from treatment start
36 48 60
Figure 2. Survival estimates and CIR of the whole patient population. With a median follow-up of 28.8 months, 2-year-OS (A) and DFS (B) were 56% (median duration
38 months) and 54% (median duration 32.4 months), respectively. (C) CIR, considering death in CR as a competing risk, was 33%.
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been extensively documented.24-26 Indeed, genetic/cytogenetic
abnormalities are powerful prognosticators, so that obtaining
information about their presence is essential for an optimal
decision-making process. The clinical implication is that, based
on their genetic status, patients would benefit frommore or less
aggressive postconsolidation strategy such as AuSCT and
AlloSCT or, in a more modern vision, from targeted new agents.
However, prognostic models barely based on pretreatment
covariates, such as genetic status, have a limited predictive
ability.11,27-29 This highlights not only the need to expand fur-
ther our knowledge about the genetic and molecular pattern of
AML but also the potential role of “factors after diagnosis,”
such as MRD monitoring. Therefore, integrating baseline factors
and monitoring of MRD appears a promising tool to refine and
possibly customize our outcome prediction ability in AML. This
philosophy was at the basis of the GIMEMA AML1310 protocol
in which, deviating from the classical “one-size-fits-all” approach,
we applied a risk-adapted and MRD-driven approach. AlloSCT is
N at risk (events)
0
NCCN-IR-no LAIP 47(0) 28(16) 20(6) 5(1)
NCCN-FR 138(0) 108(23) 80(11) 18(2) 3(1)
NCCN-IR 127(0) 80(40) 56(11) 21(6) 3(0)
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p= 0.026
























Figure 3. Survival estimates plotted byNCCN categories of risk. (A) Two-yearOSwas 42%, 58%, 74%, and 50%, respectively, for patients belonging to the NCCN-PR, NCCN-
IR, NCCN-FR, and NCCN-IR-no LAIP categories. (B) Two-year DFS was 45%, 61%, 61% and 48%, respectively, for patients belonging to the NCCN-PR, NCCN-IR, NCCN-FR and
NCCN-IR-no LAIP categories.
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Figure 4. Survival estimates of NCCN-IR category, plotted by the status of MRD after consolidation therapy. (A) Two-year OS of NCCN-IR MRD negative and MRD
positive patients were 79% and 70%, respectively. (B) Two-year DFS were 61% and 67%, respectively.
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generally recommended when the risk of relapse exceeds 35% to
40% if the procedure is not performed.7,10 In this view, NCCN-PR
category represents a priority and, in these patients, AlloSCT
should be performed as soon as CR is achieved. However, an
HLA-identical sibling is available for ,30% of the patients,30 and,
in reality, even ,30% receive it, due to disease recurrence.11 In
our study, utilization of any available source of stem cells resulted
in 71% of AlloSCT candidates receiving it. Adoption of this
strategy also translated to a 2-year OS and DFS of 42% and 45%,
respectively, for the NCCN-PR category (Figure 2). Such figures
compare very favorably with the 2-year OS and DFS of 20% to
30% currently reported for this category.27,29 Based on our study
design, patients belonging to the NCCN-FR category were given
AuSCT as a postconsolidation therapy. The role of AuSCT is
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Figure 5. Survival estimates of 60 patients whoseMRDwas analyzed integratingMFC and RT-qPCR. By integratingMFC and RT-qPCR, 4 categories of distinct MRD status
were identified with different duration of OS (A) and DFS (B). Patients who were double negative had a 2-year OS and DFS of 89% and 69%, respectively. Patients who were
MFCpos/PCRneg had a 2-year OS and DFS of 88% and 76%, respectively. Patients who were MFCneg/PCRpos had a 2-year OS and DFS of 87% and 65%, respectively. Finally,
patients who were double positive had a 2-year OS and DFS of 55% and 22%, respectively.
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Figure 6. Survival estimates of the 19 patients who received high dose of cytarabine versus those who received AuSCT. (A) Patients who received high dose of
cytarabine or an autologous stem cell transplant had an OS of 83% and 85%, respectively. (B) DFS was 68% and 63%, respectively.
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controversial; in 1 randomized study, it provided better DFS and
similar OS as conventional consolidation chemotherapy.31,32 In
our NCCN-FR category, 2-year OS and DFS were 74% and 61%,
respectively (Figure 3). We believe there is still a role for AuSCT;
indeed, this option has the advantage of sparing patients mul-
tiple courses of postconsolidation chemotherapy (usually high-/
intermediate-dose cytarabine). In fact, the recently revised Euro-
pean LeukemiaNet classification suggests that limiting AuSCT
toMRD-negative AMLmight improve the results.11 Based on our
limited experience, HDARAC might represent the choice for
patients with very “high-quality” CR such as those NCCN-FR
MFCneg/PCRneg (Figure 6). Management of patients belonging
to the NCCN-IR category is still controversial. For these patients,
the relapse rate after AuSCT can be as high as 50% to 55%,10 so
that this option appears as a suboptimal approach. Indeed,
AlloSCT is recommended for patients within this category.
However, in selected patients withMRD-negative CR, theremight
still be a room for AuSCT.10 In the present study, we planned
AlloSCT or AuSCT for NCCN-IR patients, based on the level of
MRD after the postconsolidation course. By making this choice,
we observed that the 2-year OS and DFS were 58% and 61%,
respectively (Figure 3). This figure compares very favorably with
recent analyses showing, for these patients, a 2-year OS and DFS
of;35% and 50%.27,29 Using this strategy, we also noted that the
2-year DFS of NCCN-IR patients was prolonged to equal that
of NCCN-FR patients (Figure 3). Finally, within the NCCN-IR
category, we focused on outcome as influenced by the post-
consolidation MRD status. By delivering AuSCT to NCCR-IR-Neg
andAlloSCT toNCCN-IR-Pos patients, we observed nodifference
in terms of 2-year OS or DFS (Figure 4). The stratification role of
MRD determination in IR patients has been recently suggested in
a prospective survey of the NCRI-AML17 trial.33 According to the
authors, anMRD-positive finding helps selecting patients who can
benefit from AlloSCT. An indirect confirmation of the importance
of MRD determination in IR category was that our 47 NCCN-IR-
no-LAIP patients who were submitted to AuSCT had the shortest
duration of 2-year OS and DFS (Figure 2). A reasonable ex-
planation is that these patients harbored significant post-
chemotherapeutic levels of MRD, meaning that AlloSCT would
have been the most appropriate choice. Our results highlight the
potent antileukemic effect exerted by AlloSCT in NCCN-IR-Pos
patients and theminimization of toxicity after AuSCT in NCCN-IR-
Neg ones. This interpretation can be extended to include the
overall population we had under investigation; indeed, gener-
ating the maximum antileukemic effort in high-risk patients
(NCCN-PR 1 NCCN-IR-Pos) and preserving from excess of tox-
icity those who are at low risk (NCCN-FR 1 NCCN-IR-Neg)
appears a very plausible goal. In this view, the integration of
different techniques for MRD monitoring may offer the chance to
improve even further our capability to discriminate prognostically
discrete subsets of patients, directing treatment more precisely.
Combining MFC and RT-qPCR for cases carrying a molecular
signature, we demonstrated that double-positive patients had the
worst prognosis. For these patients, a front-line intensified pro-
gram appears a reasonable option (Figure 5). Although there is
evidence that AlloSCT is not able to reverse the unfavorable long-
term impact of MRD positivity,34-37 we believe that a pretransplant
MRD-positive status should not be a contraindication for per-
forming it.38-40 In the study by Walter35 and Araki,37patients who
were MRD positive before the transplant had an outcome com-
parable to the one of patients with active disease. However,
these studies were retrospective; the patient population was
heterogeneous in terms of age and conditioning regimens
received, and there was a concentration of adverse karyotype
and secondary AML in the group of MRD-positive patients. Our
experience takes advantage of a prospective and homoge-
neous context in terms of therapy delivered and risk stratifi-
cation. A recent, retrospective analysis of 547 patients enrolled
in the Hemato-Oncology Foundation for Adults in the Neth-
erlands and the Swiss Group for Clinical Cancer Research
protocols indicates that, although all categories benefit from
AlloSCT, the absolute benefit was greater in pretransplant
MRD-positive than MRD-negative patients.41 Our present expe-
rience adds a piece of information favoring the use of AlloSCT in
MRD-positive patients, and future trials should possibly explore
the prognostic role of different levels of pretransplant MRD38 and
the value of posttransplant maintenance.
In conclusion, we recognize that the study suffers from some
intrinsic limitations due to the changes occurring over the time
(moremodern biologic knowledge, newAML classifications, and
an ever more frequent MRD monitoring) that make the historical
control and the study population not fully superimposable.
However, this is one of the first attempts to apply a prospective
program of risk-adapted, MRD-driven therapy, integrating upfront
genetics and postconsolidation MRD status, in AML of adults. In
the NCCN-FR category, AuSCT guarantees the same survival
expectation as multiple courses of cytarabine. In the NCCN-IR
category, AlloSCT can be avoided if MRD is not measurable; if
MRD is positive, AlloSCT can prolong OS and raise the DFS
duration to the level of NCCN-FR patients. Finally, using all the
available sources of stem cells allowed AlloSCT to be delivered
to a large proportion of the candidates, emphasizing the fea-
sibility of the trial transplant policy.
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